Scarica l'app Stockscreener
1.01
0.98%
-0.01
Dopo l'orario di chiusura:
1.01
Precedente Chiudi:
$1.02
Aprire:
$1
Volume 24 ore:
596.61K
Relative Volume:
0.77
Capitalizzazione di mercato:
$63.98M
Reddito:
$9.53M
Utile/perdita netta:
$-44.61M
Rapporto P/E:
-0.7953
EPS:
-1.27
Flusso di cassa netto:
$-38.32M
1 W Prestazione:
+7.45%
1M Prestazione:
-7.34%
6M Prestazione:
-22.31%
1 anno Prestazione:
-63.14%
Intervallo 1D:
$0.99
$1.09
Intervallo di 1 settimana:
$0.92
$1.22
Portata 52W:
$0.45
$3.20
Cue Biopharma Inc Stock (CUE) Company Profile
Nome
Cue Biopharma Inc
Settore
Industria
Telefono
617-949-2680
Indirizzo
40 GUEST STREET, BOSTON, MA
Confronta CUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
1.01 | 63.98M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-13 | Iniziato | Jefferies | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2022-11-21 | Iniziato | Piper Sandler | Overweight |
| 2022-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-03 | Iniziato | Craig Hallum | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-04-09 | Iniziato | Stifel | Buy |
| 2020-01-28 | Iniziato | BTIG Research | Buy |
| 2020-01-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Cue Biopharma Inc Borsa (CUE) Ultime notizie
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India
Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com
Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat
Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Cue Biopharma CEO to Present Clinical Updates at Piper Sandler Healthcare Conference | CUE Stock News - StockTitan
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates - MSN
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by GSA Capital Partners LLP - Defense World
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Cue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future Stability - MSN
Jefferies cuts Cue Biopharma shares target, retains buy rating on potential - Investing.com UK
Cue Biopharma earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Cue Biopharma Inc (CUE) Quarterly 10-Q Report - Quartzy
Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role - MSN
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses - TipRanks
Cue Biopharma Inc (CUE) Q3 2024 Earnings: EPS of $0.17 Beats Est - GuruFocus.com
Cue Biopharma's Cancer Drug Shows 91% Survival Rate in Phase 1 Trial, Revenue Up 57% | CUE Stock News - StockTitan
Cue Biopharma Announces Strategic Organizational Transition - GlobeNewswire
Cue Biopharma Strengthens Leadership: J&J Veteran with 15+ Drug Approvals Joins as CDO | CUE Stock News - StockTitan
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus reshapes outlook - Investing.com Australia
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - The Manila Times
Cue Biopharma to Present Latest Clinical Trial Data at Stifel Healthcare Conference | CUE Stock News - StockTitan
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting - The Manila Times
Cue Biopharma Presents Positive Updated Data from its Phase - GlobeNewswire
Cue Biopharma Cancer Drug Trial Soars: 91% Survival Rate, Shatters Expectations | CUE Stock News - StockTitan
Ballard Power Systems Inc (BLDP-T) QuotePress Release - The Globe and Mail
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Cue Biopharma authorizes more shares By Investing.com - Investing.com Australia
Cue Biopharma authorizes more shares - Investing.com India
There is no doubt that Cue Biopharma Inc (CUE) ticks all the boxes. - SETE News
Market Watch: Cue Biopharma Inc (CUE)’s Noteworthy Drop, Closing at 1.23 - The Dwinnex
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89% - Yahoo Finance
Technical analysis of Cue Biopharma Inc (CUE) stock chart patterns - US Post News
Cue Biopharma stock rallies nearly 40% on upcoming presentations - MSN
Cue Biopharma amends loan agreement, easing cash requirements - Investing.com India
Cue Biopharma Inc Azioni (CUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):